Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04909125

Breast Fractionation Study - Standard Versus Investigational Fractionation Trial - Nodal Radiation

Standard Versus Investigatioinal Fractionation Trial - Nodal Radiation

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
132 (actual)
Sponsor
Royal North Shore Hospital · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the difference in fatigue, quality of life and radiation morbidity between hypofractionated and conventional radiation to the breast, chest wall and regional lymph nodes post mastectomy or lumpectomy

Detailed description

Breast cancer is the most commonly diagnosed cancer in Australia. Radiotherapy to the breast, chest wall and regional lymph nodes for breast cancer after surgery can reduce the risk of local recurrence by 50% and reduce breast cancer mortality. Traditionally, radiotherapy is delivered in a large number of small doses i.e. 25 treatment sessions over 5 1/2 weeks. Another approach is to give a lower number of larger doses i.e. 15 sessions over 3 1/2 weeks (hypofractionated radiotherapy). Several studies in Europe and Asia have investigated hypofractionated radiotherapy to the chest wall, breast and regional lymph nodes following surgery for breast cancer, and found that it is equally effective to standard treatment, with similar side effects. These two approaches have not been directly compared in Australia. This trial is to compare these two approaches, to determine whether hypofractionated radiotherapy is better tolerated by patients.

Conditions

Interventions

TypeNameDescription
RADIATIONHypofractionated radiotherapy VS Standard/Conventional fractionation radiotherapyThe purpose of this study is to investigate toxicity following standard conventional fractionation versus moderately hypofractionated radiotherapy to the breast, chest wall and regional lymph nodes

Timeline

Start date
2021-06-01
Primary completion
2024-07-31
Completion
2027-12-31
First posted
2021-06-01
Last updated
2026-02-06

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT04909125. Inclusion in this directory is not an endorsement.